5 completed, 4 recruiting, 4 unknown, 1 not yet recruiting. 9 Phase 2, 4 Phase 1, 2 Not applicable, 1 Phase 3, 1 Phase 4.
Follow aGVHD: new trials by email Literature Review of aGVHD trials Research Report on aGVHD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GMPA Versus PPI for Gastric Protection and aGVHD Risk Teprenone, Esomeprazole - Hematopoietic Stem Cell Transplantation (HSCT), aGVHD | Not applicable | Recruiting | First Affiliated Hospital of Zhejiang University | 198 | 2026-09-15 | 2026-08-28 |
| A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation Ivarmacitinib - aGVHD | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 32 | 2026-02-14 | 2026-02-02 |
| Study of Gecacitinib-corticosteroid as First-line Therapy for Grade II-IV Acute Graft Versus Host Disease Gecacitinib-Corticosteroid, Methylprednisolone sodium succinate - aGVHD | Phase 2 | Recruiting | Bin Gu | 25 | 2026-01-01 | 2026-09-23 |
| BPC2001 for the Prevention of Acute Graft-Versus-Host Disease Following Haploidentical Stem Cell Transplantation BPC-2001 - Graft -Versus-host-disease, aGVHD | Phase 2 | Recruiting | BioPhoenix Co., Ltd. | 50 | 2025-10-29 | 2026-08-17 |
| Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood Haplo-Identical / Cord Blood Transplant - aGVHD, Acute Myelogenous Leukemia | Phase 2 | Recruiting | Case Comprehensive Cancer Center | 36 | 2025-08-13 | 2026-09-15 |
| Safety and Efficacy Study of hAESCs Therapy for aGVHD Human Amniotic Epithelial Stem Cell Injection - GVHD,Acute, aGVHD | Phase 1 | Completed | Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China | 10 | 2024-02-19 | 2026-10-15 |
| Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease hUC-MSCs, glucocorticoids - aGVHD | Not applicable | Unknown | Institute of Hematology & Blood Diseases Hospital, China | 182 | 2022-09-01 | 2022-09-07 |
| A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR) Itolizumab, EQ001 Placebo - Graft Versus Host Disease, GVHD | Phase 3 | Terminated | Equillium | 158 | 2022-04-29 | 2025-06-17 |
| First Line Therapy for High Risk Acute GVHD Ruxolitinib, Corticosteroid - aGVHD, Stem Cell Transplant Complications | Phase 2 | Completed | Chinese PLA General Hospital | 198 | 2019-08-25 | 2023-11-29 |
| A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD EQ001, EQ001 Placebo - Acute-graft-versus-host Disease, aGVHD | Phase 1 / Phase 2 | Completed | Biocon Limited | 30 | 2019-07-15 | 2026-06-11 |
| Efficacy and Safety Study of 4-Day ATG Regimen for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT Rabbit ATG - aGVHD, cGVHD | Phase 2 | Unknown | Chinese PLA General Hospital | 60 | 2019-02-01 | 2022-02-22 |
| Low Dose Ruxolitinib in Combination With Methylprednisolone Ruxolitinib 10 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg twice a day combined with Corticosteroids, Ruxolitinib 5 mg once a day combined with Corticosteroids - aGVHD, Stem Cell Transplant Complications | Phase 1 / Phase 2 | Completed | Chinese PLA General Hospital | 38 | 2019-01-01 | 2021-12-14 |
| Biomarker Study for Prediction of aGVHD aGVHD | Unknown | Shanghai Jiao Tong University School of Medicine | 250 | 2016-12-01 | 2018-08-06 | |
| Valproic Acid With Methylprenisonlone for the Treatment of Acute GVHD VPA - Peripheral Blood Stem Cell Transplantation, aGVHD | Phase 2 | Unknown | Shanghai Jiao Tong University School of Medicine | 55 | 2016-07-01 | 2016-08-01 |
| Efficacy and Safety Study of ATG for Prophylaxis of aGVHD in Matched Sibling Donor PBSCT ATG, CsA, mycophenolate mofetil - aGVHD | Phase 4 | Completed | Chinese PLA General Hospital | 100 | 2016-01-01 | 2022-05-24 |
Graft vs Host Disease (3) · Infections (1) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Immune System Diseases (4) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immunoproliferative Disorders (1) · Leukemia (1) · Leukemia, Lymphoid (1) · Leukemia, Myeloid (1) · Lymphatic Diseases (1) · Lymphoproliferative Disorders (1) · Neoplasms (1) · Neoplasms by Histologic Type (1)
Adrenal Cortex Hormones (2) · Antilymphocyte Serum (2) · itolizumab (2) · ruxolitinib (2) · Cyclosporins (1) · Esomeprazole (1) · Glucocorticoids (1) · KRN 7000 (1) · Methotrexate (1) · Methylprednisolone Hemisuccinate (1) · Mycophenolic Acid (1) · geranylgeranylacetone (1) · ivarmacitinib (1) · thymoglobulin (1)
Chinese PLA General Hospital (4) · Institute of Hematology & Blood Diseases Hospital, China (2) · Shanghai Jiao Tong University School of Medicine (2) · Bin Gu (1) · BioPhoenix Co., Ltd. (1) · Biocon Limited (1) · Case Comprehensive Cancer Center (1) · Equillium (1) · First Affiliated Hospital of Zhejiang University (1) · Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China (1)
China (11) · United States (3) · Australia (1) · Belgium (1) · Canada (1) · France (1) · Germany (1) · Israel (1) · Italy (1) · New Zealand (1) · Portugal (1) · South Korea (1) · Spain (1)
Daihong Liu (2) · Daihong Liu, Doctor (2) · Erlie Jiang (1) · Jiong HU, M.D. (1) · Jiong HU, M.D., (1) · Joel Rothman (1) · Leland Metheny, MD (1) · Xiaodong Mo, PhD (1) · Xiaojun Huang, M.D., PhD (1)
PMID 35668528, PMID 39438467, PMID 26228813, PMID 27892949, PMID 30808685, PMID 31958417, PMID 32119132, PMID 33536914, PMID 33663084, PMID 35123640, PMID 35484649, PMID 37341189